Armagen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2001-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.armagen.com
Clinical Trials
5
Active:0
Completed:5
Trial Phases
1 Phases
Phase 1:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (100.0%)Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- ArmaGen, Inc
- Target Recruit Count
- 19
- Registration Number
- NCT03071341
- Locations
- 🇧🇷
HCPA - Hospital das Clinicas de Porto Alegre, Porto Alegre, RS, Brazil
Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- ArmaGen, Inc
- Target Recruit Count
- 21
- Registration Number
- NCT03053089
- Locations
- 🇧🇷
HCPA - Hospital das Clinicas de Porto Alegre, Porto Alegre, RS, Brazil
Extension Study of AGT-181-102 to Evaluate Long Term Safety and Activity of AGT-181
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- ArmaGen, Inc
- Target Recruit Count
- 3
- Registration Number
- NCT02597114
Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I
Phase 1
Completed
- Conditions
- Mucopolysaccharidosis I
- Interventions
- Drug: AGT-181 (HIRMAb-IDUA)
- First Posted Date
- 2015-02-25
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- ArmaGen, Inc
- Target Recruit Count
- 3
- Registration Number
- NCT02371226
- Locations
- 🇺🇸
Children's Hospital Oakland, Oakland, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸Emory Healthcare, Decatur, Georgia, United States
Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- ArmaGen, Inc
- Target Recruit Count
- 6
- Registration Number
- NCT02262338
- Locations
- 🇺🇸
Children's Hospital Oakland, Oakland, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸Emory University, Decatur, Georgia, United States
News
No news found